Mini-abstract
Background
Material and methods
Protocol registration
Search strategy and selection criteria
Eligibility and inclusion/exclusion criteria
Study selection and data retrieval
Methodological and reporting quality assessment
Statistical analysis
Results
Search results
Study | Year | Compliance of AMSTAR/overall confidence | PRISMA scores | Cancer | Study design | Effect size | No. of studies |
---|---|---|---|---|---|---|---|
Qin [22] | 2013 | 9/critically low | 21 | Bladder cancer | Cohort | RR | 11 |
Sun [23] | 2015 | 9/critically low | 21 | Bladder cancer | Cohort | RR | 15 |
Zhao [24] | 2017 | 13/critically low | 23 | Bladder cancer | Cohort | RR | 14 |
Bagheri [25] | 2016 | 7/critically low | 17.5 | Kidney cancer | Cohort | HR | 8 |
Bergström [26] | 2001 | 4/critically low | 15.5 | Kidney cancer | Cohort, case-control | RR | 29 |
Ildaphonse [27] | 2009 | 3/critically low | 12.5 | Kidney cancer | Cohort | OR, RR | 27 |
Mathew [28] | 2009 | 4/critically low | 13 | Kidney cancer | Cohort | OR, RR | 28 |
Wang [29] | 2014 | 7/critically low | 23 | Kidney cancer | Cohort | RR | 21 |
Zhang [30] | 2018 | 10/critically low | 21.5 | Kidney cancer | Cohort | HR | 19 |
Chen [31] | 2016 | 9/critically low | 22.5 | Prostate cancer | Cohort, case-control | RR | 9 |
Discacciati [32] | 2012 | 9/critically low | 19.5 | Prostate cancer | Cohort | RR | 12 |
Jiang [33] | 2017 | 12/critically low | 19.5 | Prostate cancer | Cohort | RR | 9 |
MacInnis [34] | 2006 | 6/critically low | 24 | Prostate cancer | Cohort | RR | 56 |
Xie [35] | 2017 | 10/critically low | 20.5 | Prostate cancer | Cohort | RR | 21 |
Zhang [36] | 2015 | 9/critically low | 18.5 | Prostate cancer | Cohort, case-control | RR | 17 |
Zhong [37] | 2016 | 8/critically low | 24.5 | Prostate cancer | Cohort, case-control | RR | 24 |
Guh [38] | 2009 | 8/critically low | 18.5 | Prostate cancer Kidney cancer | Cohort | RR | 13 |
Fang [39] | 2018 | 11/critically low | 23 | Prostate cancer Kidney cancer Bladder cancer | Cohort | RR | 87 |
Al-Zalabani [40] | 2016 | 10/critically low | 25.5 | Bladder cancer | Cohort | RR | 26 |
Wang [41] | 2016 | 9/critically low | 24.5 | Prostate cancer Kidney cancer | Cohort | RR | 59 |
Robinson [42] | 2008 | 7/critically low | 21.5 | Prostate cancer | Cohort, case-control | RR | 16 |
Renehan [43] | 2008 | 12/critically low | 25 | Prostate cancer Kidney cancer | Cohort, case-control | RR | 44 |
Bergstom [44] | 2001 | 4/critically low | 14.5 | Prostate cancer Kidney cancer | Cohort, case-control | RR | 17 |
Cao [45] | 2011 | 9/critically low | 19 | Prostate cancer | Cohort | RR | 8 |
Xue [46] | 2017 | 11/critically low | 23.5 | Kidney cancer Bladder cancer | Cohort | RR | 24 |
Wang [47] | 2008 | 8/critically low | 24 | Kidney cancer | Cohort, case-control | RR | 44 |
Dobbins [48] | 2013 | 7/critically low | 20.5 | Prostate cancer | Cohort, case-control | RR | 5 |
Liu [49] | 2018 | 9/critically low | 23.5 | Kidney cancer | Cohort | RR | 24 |
Hidayat [50] | 2018 | 9/critically low | 22 | Kidney cancer Prostate cancer | Cohort, case-control | RR | 18 |
Harrison et al. [51] | 2020 | 12/critically low | 25 | Prostate cancer | Cohort, case-control | OR | 21 |
Berger et al. [52] | 2019 | 12/critically low | 26 | Prostate cancer | Cohort | RR | 12 |
Study characteristics
Quality assessment
Bladder cancer
Cancer type | Overweight | Obesity | Per 5 kg/m2 | Per 1 kg/m2 | ||||
---|---|---|---|---|---|---|---|---|
RR (95% CI) | Combined RR (95% CI) | RR (95% CI) | Combined RR (95% CI) | RR (95% CI) | Combined RR (95% CI) | RR (95% CI) | Combined RR (95% CI) | |
Bladder | Sun et al. [23] 1.07 (1.01, 1.14) Zhao et al. [24] 1.03 (0.95, 1.11) Al-Zalabani et al. 1.07 (0.99, 1.16) Xue et al. [40] 1.09 (1.01, 1.17) | 1.07 (1.03, 1.1) | Qin [22] 1.1 (1.06, 1.16) Zhao et al. [24] 1.1 (1.03, 1.17) Sun at al [23]. 1.1 (1.06, 1.14) Al-Zalabani et al. [40] 1.1 (1.03, 1.18) Xue et al. [46] 1.48 (0.89, 2.45) | 1.1 (1.07, 1.13) | Zhao et al. [24] 1.03 (1.01, 1.06) Fang et al. [39] 1.03 (1, 1.07) | 1.03 (1, 1.06) | Bergström at al [44]. 1.03 (1, 1.06) | 1.03 (1, 1.06) |
Kidney | Wang et al. [29] 1.28 (1.24, 1.33) Daphne et al. [38] 1.55 (1.47, 1.63) Xue et al. [46] 1.34 (1.11, 1.62) Wang et al. [29] 1.31 (1.23, 1.4) Liu et al. [49] 1.35 (1.27, 1.43) | 1.37 (1.26, 1.48) | Wang et al. [29] 1.77 (1.68, 1.87) Daphne et al. [38] 2.2 (1.53, 3.16) Dobbins et al. [48] 1.67 (1.55, 1.79) Liu et al. [49] 1.76 (1.61, 1.91) | 1.68 (1.47, 1.92) | Wang et al. [41] 1.25 (1.17, 1.33) Fang et al. [39] 1.2 (1.16, 1.25) Renehan et al. [43] 1.29 (1.2, 1.39) Daphne et al. [38] 1.22 (1.16, 1.28) | 1.24 (1.2, 1.28) | Bergström et al. [26] 1.07 (1.04, 1.09) Wang et al. [29] 1.04 (1.03, 1.05) Bergström et al. [44] 1.06 (1.05, 1.34) | 1.05 (1.03, 1.08) |
Prostate | 1 (0.93, 1.07) | 1.02 (0.91, 1.13) | Xie et al. [35] 1.07 (1.03, 1.12) Fang et al. [39] 1.01 (0.98, 1.03) Wang et al. [41] 1.03 (1.01, 1.05) Robinson et al. [42] 1.08 (0.97, 1.9) Dobbins et al. [48] 1.06 (0.99, 1.14) Harrison et al. [51]e 0.99 (0.96, 1.02) Berger et al. [52] 1.02 (0.94, 1.11) | 1.02 (1.01, 1.03) | Bergström at al [44]. | 1.01 (1, 1.02) |
Stratification criteria | Overweight, RR (95% CI) | Obesity, RR (95% CI) | Per 5 kg/m2, RR (95% CI) | |
---|---|---|---|---|
Sex | Male | 1.09 (0.99, 1.2) | 1.1 (1.05, 1.16) | 1.05 (1, 1.1) |
Female | 1.06 (0.99, 1.14) | 1.08 (1.02, 1.14) | 1.02 (0.96, 1.09) | |
P value | 0.647 | 0.185 | 0.474 | |
Age | Age < 50 | 1.04 (0.97, 1.13) | 1.08 (1.02, 1.14) | |
Age ≥ 50 | 1.11 (1.03, 1.19) | 1.15 (1.1, 1.2) | ||
P value | 0.224 | 0.081 | ||
Study location | Asia | 1.04 (0.99, 1.09) | 1.02 (0.97, 1.08) | |
North America | 1.12 (1.03, 1.22) | 1.13 (1.07, 1.19) | 1.06 (1, 1.12) | |
Europe | 1.09 (0.98, 1.2) | 1.06 (1.01, 1.12) | 1.02 (0.98, 1.06) | |
Asia versus North America (P value) | 0.136 | 0.008 | ||
Asia versus Europe (P value) | 0.412 | 0.312 | ||
North America versus Europe (P value) | 0.687 | 0.091 | 0.274 | |
Measure | BMI measured | 1.1 (1, 1.2) | 1.09 (1.05, 1.13) | |
BMI self-measured | 1.12 (1.04, 1.19) | 1.18 (1.1, 1.27) | ||
P value | 0.755 | 0.054 | ||
Duration | Duration of follow-up < 10 years | 1.07 (1.03, 1.11) | 1.1 (1.05, 1.16) | |
duration of follow-up ≥ 10 years | 1.07 (0.98, 1.17) | 1.1 (1.04, 1.15) | ||
P value | 1.000 | 1.000 | ||
Physical | Physical activity | 1.11 (0.99, 1.24) | 1.2 (1.08, 1.33) | |
No physical activity | 1.03 (1, 1.07) | 1.09 (1.04, 1.13) | ||
P value | 0.212 | 0.093 | ||
History | Family history of cancer | 1.15 (1.05, 1.26) | 1.15 (1.09, 1.2) | |
No family history of cancer | 1.06 (1.01, 1.11) | 1.09 (1.06, 1.13) | ||
P value | 0.120 | 0.069 | ||
Smoking | Smoking | 1.07 (0.99, 1.16) | 1.1 (1.04, 1.15) | |
No smoking | 1.1 (1.05, 1.15) | 1.11 (1.07, 1.15) | ||
P value | 0.553 | 0.774 | ||
Alcohol | Alcohol | 1.13 (1.04, 1.22) | 1.17 (1.06, 1.3) | |
No alcohol | 1.06 (0.99, 1.14) | 1.09 (1.05, 1.13) | ||
P value | 0.443 | 0.002 |
Prostate cancer
Stratification criteria | Per 5 kg/m2, RR (95% CI) | |
---|---|---|
Study location | Asia | 1.23 (0.79, 1.92) |
North America | 1.03 (1, 1.05) | |
Europe | 1.01 (0.97, 1.05) | |
Asia versus North America (P value) | 0.033 | |
Asia versus Europe (P value) | 0.014 | |
North America versus Europe (P value) | 0.409 | |
Measure | BMI measured | 1.04 (1.01, 1.07) |
BMI self-measured | 1.02 (0.98, 1.05) | |
P value | 0.397 | |
Duration | Duration of follow-up ≥ 10 years | 1.01 (0.99, 1.04) |
Duration of follow-up < 10 years | 1.04 (1.01, 1.07) | |
P value | 0.131 |
Kidney cancer
Stratification criteria | Overweight, RR (95% CI) | Obesity, RR (95% CI) | Per 5 kg/m2, RR (95% CI) | |
---|---|---|---|---|
Sex | Male | 1.28 (1.16, 1.41) | 1.65 (1.56, 1.74) | 1.18 (1.13, 1.23) |
Female | 1.51 (1.32, 1.72) | 2 (1.91, 2.08) | 1.27 (1.23, 1.32) | |
P value | 0.049 | 0.000 | 0.009 | |
Age | Age < 50 | 1.43 (1.3, 1.57) | 2.05 (1.84, 2.28) | |
Age ≥ 50 | 1.41 (1.37, 1.45) | 1.7 (1.62, 1.78) | ||
P value | 0.779 | 0.020 | ||
Study location | Asia | 1.59 (1.41, 1.8) | 2.06 (1.26, 3.37) | 1.23 (0.79, 1.92) |
North America | 1.41 (1.33, 1.46) | 1.9 (1.77, 2.04) | 1.19 (1.1, 1.28) | |
Europe | 1.22 (1.18, 1.27) | 1.67 (1.58, 1.77) | 1.19 (1.14, 1.25) | |
Asia versus North America (P value) | 0.072 | 0.750 | 0.031 | |
Asia versus Europe (P value) | 0.000 | 0.406 | 0.013 | |
North America versus Europe (P value) | 0.000 | 0.005 | 1.000 | |
Measure | BMI measured | 1.26 (1.21, 1.31) | 1.69 (1.59, 1.8) | 1.24 (1.14, 1.35) |
BMI self-measured | 1.35 (1.28, 1.42) | 1.86 (1.74, 1.99) | 1.15 (1.11, 1.2) | |
P value | 0.755 | 0.400 | 0.113 | |
Duration | Duration of follow-up ≥ 10 years | 1.28 (1.23, 1.33) | 1.78 (1.67, 1.89) | |
Duration of follow-up < 10 years | 1.32 (1.19, 1.45) | 1.76 (1.57, 1.97) | ||
P value | 0.570 | 0.864 | ||
Physical | Physical activity | 1.33 (1.24, 1.42) | 1.75 (1.58, 1.94) | |
No physical activity | 1.27 (1.21, 1.32) | 1.78 (1.67, 1.9) | ||
P value | 0.261 | 0.780 | ||
Hypertension | Hypertension | 1.36 (1.25, 1.49) | 1.93 (1.74, 2.16) | |
No hypertension | 1.27 (1.22, 1.32) | 1.72 (1.62, 1.83) | ||
P value | 0.163 | 0.069 | ||
Alcohol | Alcohol | 1.29 (1.21, 1.38) | 1.62 (1.49, 1.75) | |
No alcohol | 1.22 (1.16, 1.29) | 1.82 (1.72, 1.92) | ||
P value | 0.685 | 0.019 | ||
Smoking | Smoking | 1.25 (1.21, 1.29) | 1.1 (1.04, 1.15) | |
No smoking | 1.1 (1.05, 1.15) | 1.11 (1.07, 1.15) | ||
P value | 0.077 | 0.293 |
Association between BMI increase and mortality rates from urinary cancers
Cancer type | Mortality type | Per 5 kg/m2 | |
---|---|---|---|
RR (95% CI) | Combined RR (95% CI) | ||
Bladder | Mortality | Fang et al. [39] 1.05 (1–1.11) | 1.05 (1–1.1) |
Kidney | Mortality | Fang et al. [39] 1.21 (1.14–1.29) | 1.21 (1.14–1.29) |
Prostate | Mortality | 1.15 (1.11–1.2) | |
Prostate | Cause-specific mortality | 1.12 (1.02–1.23) | |
Prostate | All-cause mortality | Zhong et al. [37] 1.05 (0.97–1.12) | 1.05 (0.97–1.12) |